Pay in 4 interest-free payments of $6.69 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
Medical Director for UK & USMedExpress In this interview, News Medical speaks with Dr Bryony Henderson , Medical Director for the UK and US at MedExpress , about the evolving role of GLP1 agonists in obesity care and the future of metabolic health treatments
Albiglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Cardiovascular Disease (Harmony Outcomes): A Double-Blind, Randomised Placebo-Controlled Trial
Who Should Choose the Tablet Over the Injection
US$ 23.02
US$ 24.71
US$ 21.16
US$ 20.56
US$ 25.72
